1922P Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO-292)

Medullary Thyroid ◽

Patient Reported

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes

Cancer Management and Research ◽

10.2147/cmar.s127848 ◽

2019 ◽

Vol Volume 11 ◽

pp. 7893-7907 ◽

Cited By ~ 3

Author(s):

Poupak Fallahi ◽

Silvia Martina Ferrari ◽

Giusy Elia ◽

Francesca Ragusa ◽

Sabrina Rosaria Paparo ◽

...

Keyword(s):

Thyroid Cancer ◽

Cancer Patient ◽

Patient Reported Outcomes ◽

Thyroid Cancer Patient ◽

Medullary Thyroid ◽

Patient Reported

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET ‐Mutant Medullary Thyroid Cancer in the Phase 1/2 LIBRETTO‐001Trial

The Oncologist ◽

10.1002/onco.13977 ◽

2021 ◽

Author(s):

Lori J. Wirth ◽

Bruce Robinson ◽

Valentina Boni ◽

Daniel S.W. Tan ◽

Caroline McCoach ◽

...

Keyword(s):

Thyroid Cancer ◽

Patient Reported Outcomes ◽

Phase 1 ◽

Medullary Thyroid ◽

Patient Reported

A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.3522 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 3522-3522 ◽

Cited By ~ 47

Author(s):

R. Salgia ◽

S. Sherman ◽

D. S. Hong ◽

C. S. Ng ◽

J. Frye ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase I ◽

Phase I Study ◽

Kinase Inhibitor ◽

Medullary Thyroid ◽

Advanced Malignancies

Phase I trial of combination sorafenib and tipifarnib: The experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.5586 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 5586-5586 ◽

Cited By ~ 7

Author(s):

M. E. Cabanillas ◽

R. Kurzrock ◽

S. I. Sherman ◽

A. M. Tsimberidou ◽

S. Waguespack ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase I ◽

Differentiated Thyroid Cancer ◽

Phase I Trial ◽

Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.5502 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 5502-5502 ◽

Cited By ~ 10

Author(s):

R. Kurzrock ◽

E. E. Cohen ◽

S. I. Sherman ◽

D. G. Pfister ◽

R. B. Cohen ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase I ◽

Phase I Study ◽

Long Term Results ◽

442P Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

Annals of Oncology ◽

10.1016/j.annonc.2020.10.434 ◽

2020 ◽

Vol 31 ◽

pp. S1413-S1414

Author(s):

B. Keam ◽

M.I. Hu ◽

V. Subbiah ◽

L. Wirth ◽

M. Schuler ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase I ◽

Medullary Thyroid ◽

Ret Mutation

379 POSTER A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)72313-9 ◽

2008 ◽

Vol 6 (12) ◽

pp. 119 ◽

Cited By ~ 7

Author(s):

R. Kurzrock ◽

S. Sherman ◽

D. Hong ◽

C. Ng ◽

J. Frye ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase I ◽

Phase I Study ◽

Kinase Inhibitor ◽

Medullary Thyroid ◽

Advanced Malignancies

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer

The Oncologist ◽

10.1634/theoncologist.2018-0452 ◽

2018 ◽

Vol 24 (1) ◽

pp. 16 ◽

Cited By ~ 3

Author(s):

Jaydira Del Rivero ◽

Maureen Edgerly ◽

Jean Ward ◽

Ravi A. Madan ◽

Sanjeeve Balasubramaniam ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase I ◽

Locally Advanced ◽

1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1401 ◽

2020 ◽

Vol 31 ◽

pp. S1084 ◽

Cited By ~ 2

Author(s):

M. Hu ◽

V. Subbiah ◽

L.J. Wirth ◽

M. Schuler ◽

A.S. Mansfield ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase I ◽

Medullary Thyroid ◽

Ret Mutation

SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY

Endocrine Practice ◽

10.4158/ep161259.or ◽

2017 ◽

Vol 23 (2) ◽

pp. 149-156 ◽

Cited By ~ 7

Author(s):

Keita Uchino ◽

Masato Komoda ◽

Junichi Tomomatsu ◽

Takahiro Okamoto ◽

Kiyomi Horiuchi ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase I ◽

Japanese Patients ◽

Open Label ◽

Open Label Study ◽

Label Study ◽